6-(氯甲酸基)己炔羧酸乙酯 | 14794-32-2

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 6-(氯甲酸基)己炔羧酸乙酯
• 中文别名: 6-(氯甲酰基)己酸乙酯
• 英文名称: ethyl 6-(chloroformyl)hexanoate
• 英文别名: ethyl 7-chloro-7-oxoheptanoate；6-(chloroformyl)hexanoic acid ethyl ester
• CAS: 14794-32-2
• 化学式: C₉H₁₅ClO₃
• mdl: MFCD00671507
• 分子量: 206.669
• InChiKey: NYZNYLOIPHDFKS-UHFFFAOYSA-N

物化性质

• 沸点：
  141 °C / 17.5mmHg
• 密度：
  1,08 g/cm3
• 稳定性/保质期：

  常温常压下稳定，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  8
• 安全说明：
  S16,S24/25
• 危险类别码：
  R10
• 海关编码：
  2918300090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P501,P210,P234,P264,P280,P370+P378,P390,P303+P361+P353,P301+P330+P331,P363,P304+P340+P310,P305+P351+P338+P310,P403+P235,P406,P405
• 危险品运输编号：
  3265
• 危险性描述：
  H314,H227,H290
• 储存条件：
  请将产品存放在常温环境下，确保容器密封、避免光照，并保持干燥和良好的通风条件。

SDS

Ethyl 6-(Chloroformyl)hexanoate Revision number: 5
SAFETY DATA SHEET

---

Section 1. IDENTIFICATION
Product name: Ethyl 6-(Chloroformyl)hexanoate

Revision number: 5

---

Section 2. HAZARDS IDENTIFICATION
GHS classification
PHYSICAL HAZARDS
Category 1
Corrosive to metals
HEALTH HAZARDS
Category 1C
Skin corrosion/irritation
Serious eye damage/eye irritation Category 1
Not classified
ENVIRONMENTAL HAZARDS
GHS label elements, including precautionary statements
Pictograms or hazard symbols
Signal word Danger
Hazard statements May be corrosive to metals
Causes severe skin burns and eye damage
Precautionary statements:
[Prevention] Keep only in original container.
Do not breathe dust/fume/gas/mist/vapours/spray.
Wash hands thoroughly after handling.
Wear protective gloves/eye protection/face protection.
[Response] IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for
breathing.
IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,
if present and easy to do. Continue rinsing.
IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse
skin with water/shower.
Wash contaminated clothing before reuse.
Immediately call a POISON CENTER or doctor/physician.
Absorb spillage to prevent material damage.
[Storage] Store locked up.
[Disposal] Dispose of contents/container through a waste management company authorized by
the local government.
Ethyl 6-(Chloroformyl)hexanoate

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Components: Ethyl 6-(Chloroformyl)hexanoate
Percent: >97.0%(T)
CAS Number: 14794-32-2
Synonyms: 6-(Chloroformyl)hexanoic Acid Ethyl Ester , Ethyl 7-Chloro-7-oxoheptanoate
Chemical Formula: C9H15ClO3

---

Section 4. FIRST AID MEASURES
Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Inhalation:
Immediately call a POISON CENTER or doctor/physician.
Skin contact: Remove/Take off immediately all contaminated clothing. Gently wash with plenty of
soap and water. Immediately call a POISON CENTER or doctor/physician.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing.Immediately call a POISON CENTER or
doctor/physician.
Ingestion: Immediately call a POISON CENTER or doctor/physician. Rinse mouth. Do NOT
induce vomiting.
A rescuer should wear personal protective equipment, such as rubber gloves and air-
Protection of first-aiders:
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing Dry chemical, carbon dioxide.
media:
Unsuitable extinguishing Water
media:
Specific hazards arising Take care as it may decompose upon combustion or in high temperatures to
from the chemical: generate poisonous fume.
Precautions for firefighters: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protective When extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, Use extra personal protective equipment (self-contained breathing apparatus). Keep
protective equipment and people away from and upwind of spill/leak. Ensure adequate ventilation. Entry to non-
emergency procedures: involved personnel should be controlled around the leakage area by roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Absorb spilled material in a suitable absorbent (e.g. rag, dry sand, earth, saw-dust).
containment and cleaning In case of large amount of spillage, contain a spill by bunding. Adhered or collected
up: material should be promptly disposed of, in accordance with appropriate laws and
regulations.
Prevention of secondary Do not allow contact with water. Remove all sources of ignition. Fire-extinguishing
hazards: devices should be prepared in case of a fire. Use spark-proof tools and explosion-
proof equipment.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Technical measures: Handling is performed in a well ventilated place. Wear suitable protective equipment.
Prevent generation of vapour or mist. Wash hands and face thoroughly after
handling.
Use a closed system if possible. Use a ventilation, local exhaust if vapour or aerosol
will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Ethyl 6-(Chloroformyl)hexanoate

---

Section 7. HANDLING AND STORAGE
May develop pressure. Open carefully.
Use corrosive resistant equipment.
Conditions for safe storage, including any
incompatibilities
Storage conditions: Keep container tightly closed. Store in a cool and dark place.
Store under inert gas.
Protect from moisture.
Store locked up.
Store away from incompatible materials such as oxidizing agents.
Moisture-sensitive
Packaging material: Comply with laws. Keep only in original container.

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering controls: Install a closed system or local exhaust. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Half or full facepiece respirator, self-contained breathing apparatus(SCBA), supplied
air respirator, etc. Use respirators approved under appropriate government standards
and follow local and national regulations.
Impervious gloves.
Hand protection:
Eye protection: Safety goggles. A face-shield, if the situation requires.
Skin and body protection: Impervious protective clothing. Protective boots, if the situation requires.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Liquid
Form: Clear
Colorless - Slightly pale yellow
Colour:
Odour: No data available
pH: No data available
Melting point/freezing point:No data available
141°C/2.3kPa
Boiling point/range:
Flash point: No data available
Flammability or explosive
limits:
No data available
Lower:
Upper: No data available
Relative density: 1.08
Solubility(ies):
No data available
[Water]
[Other solvents] No data available

---

Section 10. STABILITY AND REACTIVITY
Chemical stability: Stable under proper conditions.
Possibility of hazardous Decomposes in contact with water and liberates toxic gases.
reactions:
Conditions to avoid: Moisture
Incompatible materials: Oxidizing agents
Hazardous decomposition Carbon monoxide, Carbon dioxide, Hydrogen chloride
products:

---

Section 11. TOXICOLOGICAL INFORMATION
No data available
Acute Toxicity:
Skin corrosion/irritation: No data available
No data available
Serious eye
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
Ethyl 6-(Chloroformyl)hexanoate

---

Section 11. TOXICOLOGICAL INFORMATION
IARC = No data available
NTP = No data available
Reproductive toxicity: No data available

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: No data available
Crustacea: No data available
No data available
Algae:
Persistence / degradability: No data available
No data available
Bioaccumulative
potential(BCF):
Mobility in soil
Log Pow: No data available
Soil adsorption (Koc): No data available
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to burn in a chemical
incinerator equipped with an afterburner and scrubber system. Observe all federal, state and local regulations when
disposing of the substance.

---

Section 14. TRANSPORT INFORMATION
Hazards Class: 8: Corrosive.
UN-No: 3265
Proper shipping name: Corrosive liquid, acidic, organic, n.o.s.
III
Packing group:

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26, 2002
and revised on February 16,2011): Safe use and production, the storage of a dangerous chemical, transport,
loading and unloading were prescribed.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-(氯甲酸基)己炔羧酸乙酯 在 sodium hydroxide 、 sodium tetrahydroborate 、 三氯化铝 、 三氟化硼乙醚 、 三氯化铁 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 8.0h， 生成 塞曲司特
  参考文献：
  名称：

  Quinones. 4. Novel eicosanoid antagonists: synthesis and pharmacological evaluation

  摘要：

  A new series of omega-phenyl-omega-quinonylalkanoic acids and related compounds was synthesized. The compounds were tested for their inhibitory effects on U-44069-induced contraction of the rabbit aorta. (+/- )-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid (4d) (AA-2414) with pA2 value of 8.28 was one of the most potent compounds. Compound 4d inhibited U-46619-induced contraction of the guinea pig lung (pA2 = 8.29) and U-44069-induced aggregation of the guinea pig platelet (IC50 = 3.5 x 10(-7) M). Compound 4d displaced the binding of [3H]U-46619 to guinea pig platelets (IC50 = 7.4 x 10(-9) M). Compound 4d also showed very potent inhibitory effects with an MED of 0.3 mg/kg (po) on U-46619-, LTD4-, PAF-, or IgG1-induced bronchoconstriction in guinea pigs. The enantiomers of 4d were prepared. The R-(+) isomer 8a was active in both in vitro and in vivo tests, but the S-(-) isomer 8b was much less active. We concluded that the antiasthmatic effects of 4d were based mainly on the TXA2 receptor antagonistic action. In addition, compound 4d showed potent inhibitory effects on PGD2-, PGF2 alpha-, and 11-epi-PGF2 alpha-induced contraction of the guinea pig tracheal strips. The diverse inhibitory effects might be expressed in terms of eicosanoid-antagonistic activity.

  DOI：

  10.1021/jm00129a030
• 作为产物：
  描述：

  庚二酸 在 氯化亚砜 、 乙醇 、 potassium hydroxide 作用下， 反应 37.5h， 生成 6-(氯甲酸基)己炔羧酸乙酯
  参考文献：
  名称：

  Novel Myocyte Enhancer Factor 2 (MEF2) modulators

  摘要：

  本公开提供了能够作为肌肉细胞增强因子2（MEF2）调节剂发挥作用的新化合物，以及组合物、药物配方、合成方法和试剂盒。还提供了使用本文提供的化合物、组合物、药物配方和试剂盒治疗可通过MEF2和/或MEF2辅因子调节的疾病的方法。

  公开号：

  US20190241504A1
• 作为试剂：
  描述：

  1-溴-3-甲基十一烷 在 6-(氯甲酸基)己炔羧酸乙酯 、 magnesium 、 cadmium(II) chloride 作用下， 生成 3-甲基十一烷
  参考文献：
  名称：

  Prout; Cason; Ingersoll, Journal of the American Chemical Society, 1948, vol. 70, p. 304

  摘要：

  DOI：

文献信息

• [EN] PYRROLOPYRIDAZINE DERIVATIVES<br/>[FR] DERIVES DE PYRROLOPYRIDAZINE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004063197A1

  公开（公告）日：2004-07-29

  The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-α mediated diseases.

  这项发明涉及公式（I）的化合物或其盐，其中R1、R2、R3和R4如描述中所定义，它们作为药物的用途，它们的制备过程以及用于治疗PDE-IV或TNF-α介导的疾病的用途。
• Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
  申请人：——

  公开号：US20030055244A1

  公开（公告）日：2003-03-20

  Disclosed are certain substituted or unsubstituted pyridyl-containing spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibiting platelet aggregation, inhibiting the binding of fibrinogen to blood platelets, and preventing or treating thrombosis

  本发明涉及某些含有取代或未取代吡啶基的螺环化合物，其取代有碱性和酸性功能，可用于抑制血小板聚集，抑制纤维蛋白原与血小板的结合，并预防或治疗血栓形成。
• .omega.-[(.omega.-Arylalkyl)aryl]alkanoic acids: a new class of specific LTA4 hydrolase inhibitors
  作者：Richard Labaudiniere、Gerd Hilboll、Alicia Leon-Lomeli、Hans Heiner Lautenschlaeger、Michael Parnham、Peter Kuhl、Norbert Dereu

  DOI：10.1021/jm00095a010

  日期：1992.8

  The synthesis and structure-activity profile of a new class of potent and specific LTA4 hydrolase inhibitors are described. Many compounds of this series of omega-[5-(omega-arylalkyl)-2-thienyl]- and omega-[4-(omega-arylalkyl)phenyl]alkanoic acids were found to be potent in vitro inhibitors of the LTB4 production by porcine leukocytes with IC50 ranging from 1 to 10 microM. The side-chain lengths were

  描述了新型有效和特异性LTA4水解酶抑制剂的合成和结构活性图。发现该系列的ω-[5-（ω-芳基烷基）-2-噻吩基]-和ω-[4-（ω-芳基烷基）苯基]链烷酸的许多化合物是有效的体外抑制LTB4产生的抑制剂猪白细胞，IC50为1至10 microM。侧链的长度对于最佳活性至关重要。亲脂性和供电子性取代基在苯系列末端芳香环上的取代作用大大增强了LTA4水解酶的抑制能力。另一方面，在噻吩系列中，这种取代对LTA4水解酶抑制的影响很小。在羧酸侧链中通过羰基或羟基的官能化导致效力较低的化合物。通过在羧酸侧链的β位插入一个氧原子，可获得代谢稳定的LTA4水解酶抑制剂RP64966。向大鼠口服施用RP64966后，发现血浆提取物显示出对LTB4生物合成的有效抑制作用（在5 mg / kg，口服时抑制40％）。
• [EN] COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE<br/>[FR] COMPOSES, PROCEDES ET PREPARATIONS DESTINES A L'APPORT ORAL D'UN COMPOSE PEPTIDIQUE DE TYPE GLUCAGON (GLP-1) OU D'UN PEPTIDE AGONISTE DU RECEPTEUR 4 DE MELANOCORTINE (MC4)
  申请人：LILLY CO ELI

  公开号：WO2005019184A1

  公开（公告）日：2005-03-03

  The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.

  本发明涉及用于口服给荷GLP-1化合物或MC4激动剂肽的新化合物、方法和配方。
• [EN] SUBSTITUTED 4-AMINO-1-BENZYLPIPERIDINE COMPOUNDS<br/>[FR] COMPOSES DE 4-AMINO-1-BENZYLPIPERIDINE SUBSTITUES
  申请人：THERAVANCE INC

  公开号：WO2005007645A1

  公开（公告）日：2005-01-27

  This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds.

  这项发明提供了4-氨基-1-苄基哌啶及其相关化合物和药学上可接受的盐，这些化合物可用作毒蕈碱受体拮抗剂。该发明还提供了含有这些化合物的药物组合物；用于制备这些化合物的有用中间体和过程；以及使用这些化合物治疗由毒蕈碱受体介导的疾病状况的方法，如膀胱过度活跃、肠易激综合征、哮喘和慢性阻塞性肺病。